Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus

Rheumatology

Volumn 43, Issue 9, 2004, Pages 1178-1181

  Bernatsky, S ^a,e   Clarke, A ^a   Ramsey Goldman, R ^c   Joseph, L ^a,b   Boivin, J F ^b   Rajan, R ^a   Moore, A D ^a   Leung, M H ^d   Allen, A ^c   Gordon, C ^d  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e NONE   (Canada)

Author keywords

Breast cancer risk; Oestrogen; Systemic lupus erythematosus

Indexed keywords

ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; ORAL CONTRACEPTIVE AGENT;

ADULT; AGE DISTRIBUTION; ANAMNESIS; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER STATISTICS; CLINICAL OBSERVATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; ESTROGEN METABOLISM; ESTROGEN THERAPY; FAMILY HISTORY; FEMALE; GENETIC PREDISPOSITION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MENARCHE; ORAL CONTRACEPTION; PARITY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; REPRODUCTIVE HEALTH; RISK ASSESSMENT; RISK FACTOR; STANDARDIZATION; STATISTICAL MODEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BREAST NEOPLASMS; CHICAGO; COHORT STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; ENGLAND; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; QUEBEC; RISK FACTORS;

EID: 4544321893     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh282     Document Type: Article

References (29)

1. Bernatsky S, Clarke A, Ramsey-Goldman R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 2002;4:351-8.
2. Bjornadal L, Lofstrom B, Yin L, Lundberg I, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002;31:66-71.
3. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:761-8.
4. Ramsey-Goldman R, Mattai SA, Schilling E, Chiu Y-L, Alo CJ, Howe HL. Increased risk of malignancy in patients with systemic lupus erythematosus. J Invest Med 1998;46:217-22.
5. Ramsey-Goldman R, Clarke A. Double trouble: are lupus and malignancy associated? Lupus 2001;10:388-91.
6. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001;10:394-400.
7. Bernatsky S, Boivin J, Joseph L et al. The prevalence of factors influencing cancer risk in lupus: social habits reproductive issues and obesity. J Rheumatol 2002;29:2551-8.
8. Colditz G, Hankinson S, Hunter D et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
9. Chlebowski R, Hendrix S, Langer R et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
10. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
11. Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer 2003;105:844-50.
12. Bernatsky S, Ramsey-Goldman R, Boivin J-F et al. Do traditional Gail model risk factors account for increased breast cancer in women with lupus? J Rheumatol 2003;30:1505-7.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982;25:1271-7.
15. Gail M, Brinton L, Byar D et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
16. Haenszel W, Loveland D, Sirken M. Lung cancer mortality as related to residence and smoking histories. J Natl Cancer Inst 1962;28:947-1001.
17. Bernatsky S, Ramsey-Goldman R, Boivin J-F et al. Cancer in systemic lupus erythematosus: an international multi-centre cohort study [abstract]. Arthritis Rheum 2003;46(Suppl. 9):S1820.
18. Abu-Rustum NR, Herbolsheimer H. Breast cancer risk assessment in indigent women at a public hospital. Gynecol Oncol 2001;81:287-90.
19. Mackarem G, Roche C, Hughes K. The effectiveness of the Gail model in estimating risk for development of breast cancer in women under 40 years of age. Breast J 2001;7:34-9.
20. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003;62:728-31.
21. Pearson JE, Silman AJ. Risk of cancer in patients with scleroderma. Ann Rheum Dis 2003;62:697-9.
22. Kubba AA. Breast cancer and the pill. J R Soc Med 2003;96:280-3.
23. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
24. Breast Cancer Collaborative Group on Hormonal Factors. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-59.
25. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
26. Karrar A, Sequeira W, Block JA. Coronary artery disease in systemic lupus erythematosus: a review of the literature. Semin Arthritis Rheum 2001;30:436-43.
27. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obesity Rev 2003;4:157-73.
28. Lahita R. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999;11:352-6.
29. Liu Z, Cheng Z, Gong R, Liu H, Liu D, Li L. Sex differences in estrogen receptor gene polymorphism and its association with lupus nephritis in Chinese. Nephron 2002;90:174-80.